PELI2 inhibits colorectal cancer development through MAPK signaling pathway.

IF 6 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Molecular Medicine Pub Date : 2025-06-12 DOI:10.1186/s10020-025-01294-3

Jialin Liu, Shengyun Hu, Liangbo Zhao, Yanmei Yang, Guanghua Wu, Yimeng Duan, Xinrui Ma, Peiwen Wang, Zhiyong Zhang, Hong Zong

{"title":"PELI2 inhibits colorectal cancer development through MAPK signaling pathway.","authors":"Jialin Liu, Shengyun Hu, Liangbo Zhao, Yanmei Yang, Guanghua Wu, Yimeng Duan, Xinrui Ma, Peiwen Wang, Zhiyong Zhang, Hong Zong","doi":"10.1186/s10020-025-01294-3","DOIUrl":null,"url":null,"abstract":"<p><p>Colorectal cancer is one of the most common malignant tumors worldwide. Colorectal cancer has a poor survival rate because it tends to metastasise to the liver and other organs. PELI2, an E3 ubiquitin ligase, is down-expressed in a variety of tumors. However, the role of PELI2 in colorectal cancer has not been revealed. In the present study, we found that expression level of PELI2 were reduced significantly in colorectal tumors compared with normal tissues. Patients with low level of PELI2 expression tended to have poor prognosis. Moreover, PELI2 decreased the proliferation, migration and anti-apoptosis of colorectal cancer cells in vitro. We also constructed xenograft tumor model to verify colorectal tumor growth slowed down after PELI2 overexpression. Transcriptome analysis suggested that PELI2 suppressed colorectal cancer progression via the MAPK signaling pathway. In brief, our study shows that PELI2 inhibits colorectal cancer development by MAPK signaling pathway.</p>","PeriodicalId":18813,"journal":{"name":"Molecular Medicine","volume":"31 1","pages":"235"},"PeriodicalIF":6.0000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12160117/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s10020-025-01294-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Colorectal cancer is one of the most common malignant tumors worldwide. Colorectal cancer has a poor survival rate because it tends to metastasise to the liver and other organs. PELI2, an E3 ubiquitin ligase, is down-expressed in a variety of tumors. However, the role of PELI2 in colorectal cancer has not been revealed. In the present study, we found that expression level of PELI2 were reduced significantly in colorectal tumors compared with normal tissues. Patients with low level of PELI2 expression tended to have poor prognosis. Moreover, PELI2 decreased the proliferation, migration and anti-apoptosis of colorectal cancer cells in vitro. We also constructed xenograft tumor model to verify colorectal tumor growth slowed down after PELI2 overexpression. Transcriptome analysis suggested that PELI2 suppressed colorectal cancer progression via the MAPK signaling pathway. In brief, our study shows that PELI2 inhibits colorectal cancer development by MAPK signaling pathway.

查看原文本刊更多论文

PELI2通过MAPK信号通路抑制结直肠癌的发展。

结直肠癌是世界范围内最常见的恶性肿瘤之一。结直肠癌的存活率很低，因为它容易转移到肝脏和其他器官。E3泛素连接酶PELI2在多种肿瘤中下调表达。然而，PELI2在结直肠癌中的作用尚未被揭示。在本研究中，我们发现与正常组织相比，PELI2在结直肠肿瘤中的表达水平明显降低。PELI2表达水平低的患者预后较差。此外，PELI2在体外还能抑制结直肠癌细胞的增殖、迁移和抗凋亡。我们还构建了异种移植肿瘤模型来验证PELI2过表达后结直肠肿瘤生长减慢。转录组分析表明，PELI2通过MAPK信号通路抑制结直肠癌的进展。总之，我们的研究表明PELI2通过MAPK信号通路抑制结直肠癌的发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Medicine 医学-生化与分子生物学

CiteScore

8.60

自引率

0.00%

发文量

137

审稿时长

1 months

期刊介绍： Molecular Medicine is an open access journal that focuses on publishing recent findings related to disease pathogenesis at the molecular or physiological level. These insights can potentially contribute to the development of specific tools for disease diagnosis, treatment, or prevention. The journal considers manuscripts that present material pertinent to the genetic, molecular, or cellular underpinnings of critical physiological or disease processes. Submissions to Molecular Medicine are expected to elucidate the broader implications of the research findings for human disease and medicine in a manner that is accessible to a wide audience.